Literature DB >> 19109219

Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation.

Amjad Hayat, Shaun R McCann, Stephen Langabeer, Sandra Irvine, Mary Frances McMullin, Eibhlin Conneally.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19109219      PMCID： PMC2635410          DOI： 10.3324/haematol.13353

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Discontinuation of imatinib therapy after achieving a molecular response.

Authors:  Jorge Cortes; Susan O'Brien; Hagop Kantarjian
Journal:  Blood       Date:  2004-10-01       Impact factor: 22.113

2.  Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

Authors:  Philippe Rousselot; Francoise Huguet; Delphine Rea; Laurence Legros; Jean Michel Cayuela; Odile Maarek; Odile Blanchet; Gerald Marit; Eliane Gluckman; Josy Reiffers; Martine Gardembas; François-Xavier Mahon
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

3.  Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry.

Authors:  M M Horowitz; P A Rowlings; J R Passweg
Journal:  Bone Marrow Transplant       Date:  1996-05       Impact factor: 5.483

4.  Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia.

Authors:  F Dazzi; R M Szydlo; C Craddock; N C Cross; J Kaeda; A Chase; E Olavarria; F van Rhee; E Kanfer; J F Apperley; J M Goldman
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

5.  Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.

Authors:  Georg Hess; Donald Bunjes; Wolfgang Siegert; Rainer Schwerdtfeger; Georg Ledderose; Barbara Wassmann; Guido Kobbe; Martin Bornhäuser; Andreas Hochhaus; Andrew J Ullmann; Thomas Kindler; Ulrike Haus; Harald Gschaidmeier; Christoph Huber; Thomas Fischer
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

6.  Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.

Authors:  E Olavarria; O G Ottmann; M Deininger; R E Clark; G Bandini; J Byrne; J Lipton; A Vitek; M Michallet; W Siegert; A Ullmann; B Wassmann; D Niederwieser; T Fischer
Journal:  Leukemia       Date:  2003-09       Impact factor: 11.528

7.  Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression.

Authors:  R H Collins; Z R Rogers; M Bennett; V Kumar; A Nikein; J W Fay
Journal:  Bone Marrow Transplant       Date:  1992-10       Impact factor: 5.483

8.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

Authors:  H J Kolb; A Schattenberg; J M Goldman; B Hertenstein; N Jacobsen; W Arcese; P Ljungman; A Ferrant; L Verdonck; D Niederwieser; F van Rhee; J Mittermueller; T de Witte; E Holler; H Ansari
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

9.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

10.  Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.

Authors:  S Mackinnon; E B Papadopoulos; M H Carabasi; L Reich; N H Collins; F Boulad; H Castro-Malaspina; B H Childs; A P Gillio; N A Kernan
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113
View more
  2 in total

1.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  David L Porter; Edwin P Alyea; Joseph H Antin; Marcos DeLima; Eli Estey; J H Frederik Falkenburg; Nancy Hardy; Nicolaus Kroeger; Jose Leis; John Levine; David G Maloney; Karl Peggs; Jacob M Rowe; Alan S Wayne; Sergio Giralt; Michael R Bishop; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-10       Impact factor: 5.742

2.  The use of imatinib mesylate as a lifesaving treatment of chronic myeloid leukemia relapse after bone marrow transplantation.

Authors:  Monika Conchon; Sabri S Sanabani; Israel Bendit; Carla Luana Dinardo; Lucia Dias; Dalton de Alencar Fischer Chamone; Pedro Enrique Dorlhiac-Llacer; Frederico Luiz Dulley
Journal:  J Transplant       Date:  2009-10-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.